Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.

EU mid-market update: Trump adds Middle East tensions to macro picture as trade war keeps volatility high; Novo Nordisk rises ...

A slowdown in Google's cloud-computing sales helped drag down Alphabet's overall revenue growth to its lowest rate since 2023. Shares tumbled about 7% ...

Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter earnings of $4.04 billion. The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...